Last reviewed · How we verify
low-dose IL-2
Low-dose IL-2 is an immunomodulatory agent being evaluated in various clinical trials for conditions such as alopecia areata, melanoma, and chronic graft-versus-host disease (cGVHD). It has shown promise in early-phase studies and is currently in multiple Phase 1 and Phase 2 trials.
At a glance
| Generic name | low-dose IL-2 |
|---|---|
| Also known as | interleukin-2 |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- low-dose IL-2 CI brief — competitive landscape report
- low-dose IL-2 updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI